ten Hacken, Elisa

Publications

Sort by

Co-Author Network

selected publications

Updates on the biology of chronic lymphocytic leukemia: introductory editorial. Seminars in hematology. 2024 Editorial Article GET IT
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. Blood. 2024 Academic Article GET IT
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial. Seminars in hematology. 2024 Editorial Article GET IT
Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing. STAR protocols. 2023 Academic Article GET IT
Mitochondrial DNA Mutations as Natural Barcodes for Lineage Tracing of Murine Tumor Models. Cancer research. 2023 Academic Article GET IT
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. Blood advances. 2022 Academic Article GET IT
In vivo modeling of CLL transformation to Richter's syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities. Blood cancer discovery. 2022 Academic Article GET IT
Understanding CLL biology through mouse models of human genetics. Blood. 2021 Review GET IT
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer research. 2021 Academic Article GET IT
Times cited: 15
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer cell. 2021 Academic Article GET IT
Times cited: 34
High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome biology. 2020 Academic Article GET IT
Times cited: 20
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia. 2020 Academic Article GET IT
Times cited: 22
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2019 Academic Article GET IT
Times cited: 18
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer cell. 2019 Academic Article GET IT
Times cited: 227
SLAMF6 as a Regulator of Exhausted CD8⁺ T Cells in Cancer. Cancer immunology research. 2019 Academic Article GET IT
Times cited: 19
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer cell. 2019 Academic Article GET IT
Times cited: 66
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia. 2018 Review GET IT
Times cited: 40
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI insight. 2018 Academic Article GET IT
Times cited: 41
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. The Journal of experimental medicine. 2018 Academic Article GET IT
Times cited: 65
SnapShot: Chronic Lymphocytic Leukemia. Cancer cell. 2017 Academic Article GET IT
Times cited: 10
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 Letter GET IT
Times cited: 10
HSP90, a chaperone that can make you SYK. Blood. 2017 Comment GET IT
Times cited: 1
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget. 2016 Academic Article GET IT
Times cited: 88
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. Journal of immunology (Baltimore, Md. : 1950). 2016 Academic Article GET IT
Times cited: 34
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016 Academic Article GET IT
Times cited: 60
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment. Blood. 2016 Academic Article GET IT
Times cited: 48
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 26
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochimica et biophysica acta. 2015 Review GET IT
Times cited: 189
Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacology & therapeutics. 2014 Review GET IT
Times cited: 47
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nature medicine. 2014 Academic Article GET IT
Times cited: 251
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Review GET IT
Times cited: 72
Targeting B-cell anergy in chronic lymphocytic leukemia. Blood. 2013 Academic Article GET IT
Times cited: 64
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. Blood. 2013 Academic Article GET IT
Times cited: 45
Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions. Leukemia. 2012 Review GET IT
Times cited: 33
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. Leukemia. 2011 Academic Article GET IT
Times cited: 33
How the microenvironment shapes chronic lymphocytic leukemia: the cytoskeleton connection. Leukemia & lymphoma. 2010 Academic Article GET IT
Times cited: 14
HS1 has a central role in the trafficking and homing of leukemic B cells. Blood. 2010 Academic Article GET IT
Times cited: 67

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Define the evolutionary trajectories of CLL undergoing Richter transformation through single-cell multi-omics awarded by Leukemia Research Foundation, Inc. Principal Investigator 2024 - 2026
Defining the epigenetic landscape and therapeutic vulnerabilities of Richter''s syndrome in CRISPR-based mouse models awarded by National Cancer Institute Principal Investigator 2023 - 2026
Characterizing and targeting aberrant NOTCH1 signaling in Richter''s syndrome awarded by CLL Global Research Foundation Principal Investigator 2024 - 2025
missing activity Principal Investigator 2023 - 2024

Uncovering MGA-driven epigenetic reprogramming in Richter''s syndrome awarded by Leukemia & Lymphoma Society, Inc. Key Personnel 2024 - 2027
Identifying B cell developmental changes and therapeutic vulnerabilities of MGA-mutant Richter''s syndrome awarded by Fondazione AIRC per la Ricerca sul Cancro Key Personnel 2024 - 2026

more ...

less ...

Background

education and training

Ph.D., San Raffaele University (Italy) 2014
M.Sc., San Raffaele University (Italy) 2009
B.Sc., University of Bologna (Italy) 2007

Contact

full name

Elisa ten Hacken

primary email

elt4010@med.cornell.edu

VIVO Weill Cornell Medical College

Elisa ten Hacken Assistant Professor of Cancer Biology in Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email